On Thursday, NewAmsterdam Pharma hit an important technical milestone, with its Relative Strength (RS) Rating climbing into the 90-plus percentile with an upgrade to 91, up from 88 the day before.
Here Are 3 Keys For Successful Stock Investing
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of over 80 at the beginning of a new price run.
NewAmsterdam Pharma is building a consolidation with a 27.29 buy point. See if it can break out in volume at least 40% above average.
The company reported 0% EPS growth in the latest quarterly report. Sales increased 825%.
NewAmsterdam Pharma holds the No. 26 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
